{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT00739934", "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1501088&StudyName=Study%20Of%20The%20Pharmacokinetics%20And%20Safety%20Of%20Voriconazole%20In%20Children%202%20To%2011%20Years%20Old%20Who%20Are%20At%20High%20Risk%20For%20Systemic%20Fungal%20"], "org_study_id": ["A1501088"], "nct_id": ["NCT00739934"], "brief_title": ["Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection"], "official_title": ["An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To <12 Years Who Are At High Risk For Systemic Fungal Infection"], "lead_sponsor": [], "source": ["Pfizer"], "has_dmc": ["No"], "textblock": ["In this study we will measure the concentration of the drug called voriconazole which is used\r\n      to fight infections caused by fungus in children who usually are cancer patients and have\r\n      their immune system down. Since we know the dose in adults, and we think we know the matching\r\n      doses in the young patients ages 2 to 12 years old, we will compare the amount of drug that\r\n      goes into the system with what we know works in adults. We give the drug by a needle directly\r\n      into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we\r\n      draw a little bit of blood at certain times to measure the drug in it."], "overall_status": ["Completed"], "start_date": ["December 2008"], "type": ["Actual", "Actual", "Actual", "Estimate", "Estimate", "Estimate"], "completion_date": ["October 2009"], "primary_completion_date": ["October 2009"], "phase": ["Phase 2"], "study_type": ["Interventional"], "has_expanded_access": ["No"], "allocation": ["Non-Randomized"], "intervention_model": ["Single Group Assignment"], "primary_purpose": ["Treatment"], "masking": ["None (Open Label)"], "measure": ["Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration", "Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration", "Time to Reach Cmax (Tmax) Following IV Administration", "AUC12,ss Following Oral Administration", "Cmax,ss Following Oral Administration", "Tmax Following Oral Administration", "AUC12 Following IV Loading Dose", "Cmax Following an IV Loading Dose", "Tmax Following an IV Loading Dose", "Trough Concentrations (Cmin)", "AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration", "Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration", "Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration", "AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration", "Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration", "Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration"], "time_frame": ["Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose", "Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose", "Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose", "Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 7 (up to Day 20 or more) for IV; Day 7 (or later) for oral at predose", "Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose", "Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose", "Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose", "Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose"], "description": ["AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.", "AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.", "AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.", "AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.", "Zero Tmax refers to the highest concentration observed for one participant at predose. The profile of the metabolite is relatively flat, which could result in slight variation in sample collection or assay process.", "AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.", "Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.", "Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h\r\nNotes:\r\nIf unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.\r\nOnly morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.\r\n(IV = Intravenous; POS = Powder for oral suspension)", "To obtain contact information for a study center near you, click here."], "number_of_arms": [1.0], "enrollment": [40.0], "condition": ["Candidiasis", "Candidemia"], "arm_group_label": ["Children aged 2 to <12 years", "Children aged 2 to <12 years"], "arm_group_type": ["Experimental"], "intervention_type": ["Drug"], "intervention_name": ["voriconazole (Vfend)"], "other_name": ["UK-109,496; Vfend; voriconazole"], "criteria": [], "gender": ["All"], "minimum_age": ["2 Years"], "maximum_age": ["11 Years"], "healthy_volunteers": ["No"], "last_name": ["Pfizer CT.gov Call Center"], "role": ["Study Director"], "affiliation": ["Pfizer"], "facility": [], "country": ["United States"], "verification_date": ["January 2011"], "study_first_submitted": ["August 20, 2008"], "study_first_submitted_qc": ["August 21, 2008"], "study_first_posted": ["August 22, 2008"], "results_first_submitted": ["September 17, 2010"], "results_first_submitted_qc": ["January 6, 2011"], "results_first_posted": ["January 25, 2011"], "last_update_submitted": ["January 26, 2011"], "last_update_submitted_qc": ["January 26, 2011"], "last_update_posted": ["January 28, 2011"], "name_title": ["Director, Clinical Trial Disclosure Group"], "organization": ["Pfizer, Inc."], "keyword": ["Open-Label", "Pharmacokinetics", "Intravenous to oral switch", "Safety", "Voriconazole", "Immunocompromise", "Children", "High Risk For Systemic Fungal Infection."], "mesh_term": ["Candidemia", "Voriconazole"], "participant_flow": [], "baseline": [], "outcome_list": [], "reported_events": [], "certain_agreements": [], "point_of_contact": []}